.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Healthtrust
Medtronic
US Army
Covington
Cerilliant
Argus Health
Chinese Patent Office
Merck
Colorcon

Generated: September 22, 2017

DrugPatentWatch Database Preview

Nextwave Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for NEXTWAVE PHARMS, and what generic alternatives to NEXTWAVE PHARMS drugs are available?

NEXTWAVE PHARMS has one approved drug.

There are seven US patents protecting NEXTWAVE PHARMS drugs.

There are twenty-five patent family members on NEXTWAVE PHARMS drugs in fourteen countries.

Summary for Applicant: Nextwave Pharms

Patents:7
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Nextwave Pharms
QUILLIVANT XR
methylphenidate hydrochloride
FOR SUSPENSION, EXTENDED RELEASE;ORAL202100-001Sep 27, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Nextwave Pharms
QUILLIVANT XR
methylphenidate hydrochloride
FOR SUSPENSION, EXTENDED RELEASE;ORAL202100-001Sep 27, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Nextwave Pharms
QUILLIVANT XR
methylphenidate hydrochloride
FOR SUSPENSION, EXTENDED RELEASE;ORAL202100-001Sep 27, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Nextwave Pharms
QUILLIVANT XR
methylphenidate hydrochloride
FOR SUSPENSION, EXTENDED RELEASE;ORAL202100-001Sep 27, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Nextwave Pharms
QUILLIVANT XR
methylphenidate hydrochloride
FOR SUSPENSION, EXTENDED RELEASE;ORAL202100-001Sep 27, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Nextwave Pharms
QUILLIVANT XR
methylphenidate hydrochloride
FOR SUSPENSION, EXTENDED RELEASE;ORAL202100-001Sep 27, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Nextwave Pharms
QUILLIVANT XR
methylphenidate hydrochloride
FOR SUSPENSION, EXTENDED RELEASE;ORAL202100-001Sep 27, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for NEXTWAVE PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
methylphenidate hydrochloride
Extended-release Oral Suspension5 mg/mL
QUILLIVANT XR
8/2/2013

Non-Orange Book Patents for Nextwave Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,675,703Modified release formulations containing drug - ion exchange resin complexes► Subscribe
9,675,704Modified release formulations containing drug-ion exchange resin complexes► Subscribe
8,202,537Modified release formulations containing drug-ion exchange resin complexes► Subscribe
8,747,902Modified release formulations containing drug-ion exchange resin complexes► Subscribe
8,597,684Modified release formulations containing drug-ion exchange resin complexes► Subscribe
8,491,935Modified release formulations containing drug-ion exchange resin complexes► Subscribe
9,549,989Modified release formulations containing drug-ion exchange resin complexes► Subscribe
9,198,864Modified release formulations containing drug-ion exchange resin complexes► Subscribe
9,522,191Modified release formulations containing drug--ion exchange resin complexes► Subscribe
8,337,890Modified release formulations containing drug-ion exchange resin complexes► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Nextwave Pharms Drugs

Country Document Number Estimated Expiration
Russian Federation2435569► Subscribe
Canada2825991► Subscribe
Israel227734► Subscribe
South Korea101495146► Subscribe
Israel194042► Subscribe
Taiwan200812649► Subscribe
European Patent Office2428205► Subscribe
Austria536867► Subscribe
Japan2009530298► Subscribe
China101400343► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Citi
McKinsey
Express Scripts
Teva
Julphar
Mallinckrodt
McKesson
Healthtrust
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot